Research ArticleClinical Investigation

Biodistribution of 18F-FES in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant (G1T48), a Novel Selective ER Degrader

Ramsha Iqbal, Maqsood Yaqub, Daniela E. Oprea-Lager, Yeukman Liu, Anne Marije Luik, Andy P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard and Catharina W. Menke-van der Houven van Oordt
Journal of Nuclear Medicine May 2022, 63 (5) 694-699; DOI: https://doi.org/10.2967/jnumed.121.262500

Article Figures & Data

Figures

  • Figure
  • FIGURE 1.
    FIGURE 1.

    Venous blood sampling data of all patients obtained at the 3 different time points. (A) SUV whole blood data. (B) Plasma-to-whole blood ratios. (C) Parent fraction of 18F-FES in plasma. Data represent median of all values, with their corresponding IQRs.

  • FIGURE 2.
    FIGURE 2.

    Tracer uptake in blood pool of each patient at 3 different time points. Whole blood calibrated with venous samples (A), plasma (B), and metabolite-corrected plasma (C) input curves. All curves have been corrected for administered dose and weight. At time of progression, patients were scanned ≤2 d (blue curves) or ≥6 d (green curves) after EoT. * P < 0.05

  • FIGURE 3.
    FIGURE 3.

    Visual assessment of 18F-FES uptake in various healthy tissues in 1 patient at baseline (A), interim (B), and after treatment (C). This patient underwent interim scanning 10 d after EoT. Uterus, an ER-expressing organ, is not visible in these images as it is located behind bladder. Images are maximal-intensity projections.

  • FIGURE 4.
    FIGURE 4.

    SUV time–activity curves (derived from dynamic scans) for various healthy tissue regions ([A] breast, [B] liver, [C] muscle, [D] bone. and [E] lung) of all patients at 3 different time points. Curves represent median of all values, with their corresponding IQRs.

Additional Files

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords